Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Monday, November 02, 2026

Ganga Pharmaceuticals Limited CIN: L99999MH1989PLC053392 Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305 Phone: 9834613142 | Website: www.ayurvedganga.com. | Email: ayurvedganga@gmail.com. November 02, 2026 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400 001 Scrip Code: 539680 Sub: Intimation pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) - Outcome of the Board Meeting - Financial Results Dear Sir/Madam, Pursuant to Regulations 30 and 33 of the SEBI Listing Regulations, please take note that the Board of Directors of the Company has, at its Meeting held today i.e., November 02, 2026, considered and approved, inter-alia, the Un-audited Financial Results of the Company for the half year ended September 30, 2026 along with the Limited Review Report of the Statutory Auditors thereon. The said results along with the Limited Review Report is annexed herewith. The above information is also available on the website of the Company i.e, www.ayurvedganga.com. The Board Meeting commenced at 03:40 p.m. and concluded at 4.10 p.m. Kindly take the same on records. Thanking You, Yours faithfully, For Ganga Pharmaceuticals Limited B 16152440530 Bharat Sharma Managing Director DIN: 00077026 Email Id: bharat.sharma@gangapharma.in. Encl: As above (Af BANKA & BANKA CHARTERED ACCOUNTANTS INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2026 (Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended) The Board of Director Ganga Pharmaceuticals Ltd. We have reviewed the accompanying Statement of unaudited financial results of Ganga Pharmaceuticals Ltd (“the Company”) for the half year ended 30 September 2026 (‘the Statement’). This Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries made of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the applicable Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. Yours Faithfully, For BANKA & BANKA CHARTERED ACCOUNTANTS CAI FIRM REG. NO.: 100979W Qdeso (Pradeep P. Banka) Partner Membership No.: - 038800 UDIN: 26028800TMTORLY30Y Mumbai :- 02/11/2026 CORRESPONDENCE OFFICE : Shah Trade Centre, 3rd Floor, 3rd Floor, Rajan House, Dr. Annie Besant Above State Bank of India, Off: 022 40984545 info@bankabanka.com Road, Prabhadevi, Opp. Century Bazar, Rani Sati Marg, Off. W. E. Highway, Fax: 022 40984546 www.bankabanka.com Mumbai - 400025. Maharashtra Malad (E), Mumbal - 400097. GANGA PHARMACEUTICALS LIMITED ‘CIN: L99999MH1989PLC053392 REGISTERED OFFICE ADDRESS: G ANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401 305. Phone No.9967840111 Email id: ayurvedaganga@gmail.com , Website: www.ayurvedganga.com Statoef Umn-eAudnitted Financial Results for the Half and Year ended 30th September 2026. Rs.in Lakhs & Figures for the half year ended on eF in ea an dc ii ea dl ou| l yvaF ri n sa nn dc ei dal ool o Particulars 30-0920% | 31032026 | 30092025 | 31032026 | 3103-205 (Un-Audited) | (Audited) | (Un-Audited) | (Audited) | (Audited) 1 [INCOME FROM OPERATIONS. (a) Revenue from operations 14163 1614 13665 w79 26374 (b) Other Income 1364 1311 1480 2791 4359 Total Income 15527 15145 4691 31070 30733 2 |Expenses: (@) Cost of Materials consumed 8042 4914 7004 119.18 12055 |(b) Purchase of stock in trade () Change in inventorieosf finished goods & packing [Material @72) 1853 737)| 116 093 (d) Employee Benefit Expenses 27 2636 3197 5853 771 (¢) Finance Cost 553 666 664 1330 1785 /(6 Depreciation and Amortization Expense 281 305 254 559 465 |(8) Other Administrative Expenses 3899 4542 4429 8971 9618 Total Expenses 15276 148,10 14416 29777 29786 3 [Profit/(Loss) before Tax (1-2) 252 958 335 1293 947 4 [Tax Expenses (a) Current Tax 091 221 082 303 148 |(b) Deffered Tax (026) (030)| 005 025) 009 5 [Net Profit / (Loss) for the period (3-4) 186 248 550 1015 750 6 [Other Comprehensive Income 7 [P- aUp iequidty share capital (Equity Shaorf Res. 10/- each) 59115 59115 59115 59115 45365 8 [Eaming per equity share (Rs.) (1) Basic 003 013 004 017 016 (2) Diluted 003 013 004 017 012 GANGA PHARMACEUTICALS LTD . CIN: L99999MH1989PLC053392 " Registered Office: Gangatat, Dhanvantari Marg,G opcharpada, Virar (East), Palghar <401 305. Phone No.9967840111 ; Website: www.ayurvedganga.com; Email id:ayurvedaganga@gmail.com Statement of Un-Audited Assests and Liabilities as at 30th September 2026 Rs.in Lakhs TR < Asat Asat Statement of Assets and Liabilities Particulars (30-09-2026) (31-03-2026) A [EQUITY AND LIABILITIES (1) Shareholders Funds: (a) Share Capital P115 591.15 (b) Reserve & Surplus 24198 24011 (C)Money received against share warrants - - (2) Non-Current Liabilities () Long-Term Borrowings 1398 981 (b) Deferred Tax Liabilities (Net) 0.06 032 (¢) Other Long Term Liabilities = (d) Long Term Provisions s (3) Current Liabilities () Short-term borrowings 10863 99.19 (b) Trade payables i) Total outsatnding dues of micro enterprises and small enterprises - (0.00) i) Total outsatnding dues of creditors other then micro enterprisaensd small enterprises 13.68 1180 (c) Other current liabilities 9.50 9.52 (d) Short-term provisions 402 303 Total 983.01 964.93 B |ASSETS (1) Non - Current assets (a) Fixed Assets 6260 6457 (b) Non-current investments - - () Deferred tax assets (net) s 2 (d) Long term loans and advances - - (¢) Other Non-current assets 14392 14392 (2) Current assets (a) Current Investment - (b) Inventories 11638 11652 (c) Trade receivables 105.65 93.90 ( (d )) SC ha os rh t -a tn ed r mc a ls oh an e sq aui nv da l ae dn vt as n ces 3162 51 87 7 295 258 32 (£) Other current assets 23541 24768 Total 983.01 964.93 GANGA PHARMACEUTICALS LIMITED (CIN: L9999IMH1989PLC053392) Cash Flow Statement for the half year ended 30th Septmber 2026. Half Year ended Half Year ended Year ended Year ended 30th September 2026 30th September 2026 31st March 2026 31st March 2026 (Rs. In lakhs) (Rs. In lakhs) (Rs. In lakhs) (Rs. In lakhs) A. Cash flow from operating activities: Net profit before tax as per Profit and Loss . 252 1293 Account. Adjustment to reconcile profit before tax to net cash flows : Depreciation and amortisation expense 281 559 Interest on advance & deposit recd (13.69) D (27.91) Finance cost 553 1231 Profit on Sale of Shares = = (5.30) (10.01) Operating profit before working capital (2.79) 292 changes Movements in working capital: (Decrease) / Increase in trade payables 188 (15.96) (Decrease)/ Increase in other liabilities (0.02) (2.61) (Decrease)/ Increase in Short term 9.44 (19.75) borrowing (Decrease) / Increase in Short term 099 155 Provision (Increas [Showing first 8,000 characters — download PDF for full document]